Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Ketone doai
Reexamination Certificate
2008-03-18
2008-03-18
Kim, Jennifer (Department: 1617)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Ketone doai
C514S521000, C514S626000, C514S676000, C514S683000, C514S727000
Reexamination Certificate
active
10684777
ABSTRACT:
The present invention relates to the use of compounds and composition of compounds that modulate norepinephrine levels for the prevention and treatment of vasomotor symptoms, such as hot flush, caused by, inter alia, thermoregulatory dysfunctions.
REFERENCES:
patent: 3454554 (1969-07-01), Biel et al.
patent: 4229449 (1980-10-01), Melloni et al.
patent: 4310524 (1982-01-01), Wiech et al.
patent: 4535186 (1985-08-01), Husbands et al.
patent: 4826844 (1989-05-01), Husbands et al.
patent: 5146927 (1992-09-01), Czeisler et al.
patent: 5502047 (1996-03-01), Kavey
patent: 2002/0107249 (2002-08-01), Wong et al.
patent: 2002/0128173 (2002-09-01), Wong et al.
patent: 2003/0036923 (2003-02-01), Waldon et al.
patent: 2003/0216366 (2003-11-01), Leonard et al.
patent: 0 065 757 (1982-12-01), None
patent: 0 303 961 (1989-02-01), None
patent: 0 208 235 (1990-01-01), None
patent: 1 266 659 (2002-12-01), None
patent: 91/18602 (1991-12-01), None
patent: WO98/36744 (1998-08-01), None
patent: 99/44601 (1999-09-01), None
patent: 02/064543 (2002-08-01), None
patent: 03/037334 (2003-05-01), None
patent: 03/077897 (2003-09-01), None
Spence et al. Milnacipran A review of its use in depression. Drugs Sep. 1998: 56(3): pp. 405-427.
Berendsen The role of serotonin in hot flushes. Maturitas 36 (2000) p. 155-164.
Clinical Trial: “Phase III Randomized Study of Medroxyprogesterone Versus Venlafaxine in Women With Symptomatic Hot Flashes”, www.clinicaltrials.gov sponsored by the National Institutes of Health, Study ID Numbers: CDR0000069217; NCCTG-N99C7; NCI-P02-0204, 2003, 6 pages.
Acs, N. et al., “Estrogen improves impaired musculocutaneous vascular adrenergic reactivity in pharmacologically ovariectomized rats: a potential peripheral mechanism for hot flashes?”,Endocrinology, 2001 15: 68-73.
Barlow, D. H., “Venlafaxine for hot flushes,”Lancet, Dec. 16, 2000, 356(9247): 2025-2026.
Barton, D. et al., “Hot Flashes—Aetiology and Management,”Drugs and Aging, 2001, 18(8): 597-606.
Berendsen, H. H. G., “Hot Flushes and serotonin,”Journal of the British Menopause Society, Mar. 2002, 8(1): 30-34.
Berendsen, H. H. G., “Effect of tibolone and raloxifene on the tail temperature of oestrogen-deficient rats,”European Journal of Pharmacology, 2001, 419(1): 47-54.
Berendsen, H. H. G., “The role of serotonin in hot flushes,”Maturitas, 2000, 36(3): 155-164.
Bundgaard, H., “Means to enhance penetration; Prodrugs as a means to improve the delivery of peptide drugs,”Advanced Drug Deliver Reviews, 1992, 8, 1-38.
Bundgaard, H. et al., “Glycolamide Esters as Biolabile Prodrugs of Carboxylic Acid Agents: Synthesis, Stability, Bioconversion, and Physicochemical Properties,” J. of Pharmaceutical Sciences, Apr. 1988, 77(4):285.
Casper, R. F. et al., “Neuroendocrinology of menopausal flushes: an hypothesis of flush mechanism,”Clinical Endocrinology, 1985, 22: 293-312.
Fink, G. et al., “Oestrogen and mental state,”Nature, 1996, 383(6598): 306.
Freedman, R. R. et al., “Clonidine raises the sweating threshold in symptomatic but not asymptomatic postmenopausal women,”Fertility&Sterility, 2000, 74(1): 20-3.
Freedman, R. R., “Physiology of hot flashes,”American Journal of Human Biology, 2001, 13: 453-464.
French, N., “α2-Adrenoceptors and I2sites in the mammalian central nervous system,”Pharmacol. Ther., 1995, 68(2):175-208.
Janowsky, et al., “Desipramine: an overview,”Journal of Clinical Psychiatry, 1984, 45(10 Pt 2): 3-9.
Katovich, M. J. et al., “Mechanisms mediating the thermal response to morphine withdrawal in rats”,Proceedings of the Society for Experimental Biology&Medicine, 1990, 193(2): 129-35.
Katovich, M. J. et al., “Alpha-adrenergic mediation of the tail skin temperature response to naloxone in morphine-dependent rats,”Brain Research, 1987, 426: 55-61.
Kramer et al., In: Murphy et al.,3rdInt'l Symposium on Recent Advances in Urological Cancer Diagnosis and Treatment-Proceedings, Paris, France: SCI: 3-7 1992.
Krogsgaard-Larsen, et al., (ed). Design and Application of Prodrugs, Textbook of Drug Design and Development, Chapter 5, 113-191 1991.
Kronenberg et al., “Thermoregulatory Physiology of Menopausal Hot Flashes: A Review,”Can. J. Physiol. Pharmacol., 1987, 65:1312-1324.
Loprinzi, C.L. et al., “Venlafaxine in management of hot flashes in survivors of breast cancer: a randomized controlled trial,”Lancet, Dec. 16, 2000, 356(9247): 2059-2063.
Loprinizi, C. L. et al. “Pilot Evaluation of Venlafaxine Hydrochloride for the Therapy of Hot Flashes in Cancer Survivors,”Journal of Clinical Oncology, Jul. 1998, 16(7): 2377-2381.
Mackinnon et al., “α2-Adrenoceptors: more subtypes but fewer functional differences,”TIPS, 1994, 15: 119-123.
Merchenthaler et al., “The effect of estrogens and antiestrogens in a rat model for hot flush,”Maturitas, 1998, 30(3): 307-316.
Morin, S. M., “Atomoxetine Selectively Induces Fos Expression in the Rat Prefrontal Cortex,” Presented at Society for Neuroscience Annual Meeting (SFN); Nov. 2-7, 2002, Orlando, FL.
Pacholczyk, T. et al., “Expression cloning of a cocaine-and antidepressant-sensitive human noradrenaline transporter,”Nature, 1991, 350(6316): 350-4.
Panek, D.U. et al., “Effect of continuous intraventricular estrogen or catechol estrogen treatmetn on catecholamine turnover in various brain regions,”J. Pharmacol. Exp. Ther., 1986, 236(3), 646-652.
Prasad, P.D., et al., “Functional expression of the plasma membrane serotonin transporter but not the vesicular monoamine transporter in human placental trophoblasts and choriocarcinoma cells,” Placenta, 1996, 17(4): 201-7.
Quella, S. K. et al., “Pilot evaluation of Venlafaxine for the treatment of hot flashes in men undergoing androgen ablation therapy for prostate cancer,”The Journal of Urology, Jul. 1999, 162: 98-102.
Reneric, J-Ph. et al., “Idazoxan and 8-OH-DPAT modify the behavioral effects induced by either NA, or 5-HT, or dual NA/5-HT reuptake inhibition in the rat forced swimming test,”Nueropsychopharmacology, Apr. 2001, 24(4): 379-390.
Rosenberg, J. et al., “Hypothesis: pathogenesis of postmenopausal hot flush,”Medical Hypotheses, 1991, 35: 349-350.
Shaw, C. R., “The perimenopausal hot flash: epidemiology, physiology, and treatment,”Nurse Practitioner, 1997, 22: 55-56, 61-66.
Stearns, V. et al., “Hot flushes,”Lancet, Dec. 7, 2002, 360(9348): 1851-1861.
Stearns,V. et al., “Paroxetine controlled release in the treatment of menopausal hot flashes,”JAMA, 2003, 289:2827-2834.
Stearns, V. et al., “A pilot trial assessing the efficacy of paroxetine hydrochloride (Paxil) in controlling hot flashes in breast cancer survivors,”Ann Oncol., 2000, 11:17-22.
Waldinger et al., “Treatment of hot flushes with mirtazapine: four case reports,”Maturitas, 2000, 36(3): 165-168.
Wilen, S.H.Tables of Resolving Agents and Optical Resolutions, p. 268 E.L. Eliel, Ed., University of Notre Dame Press, Notre Dame, IN 1972.
Wilen, S.H., et al., “Strategies in optical resolutions,”Tetrahedron, 33:2725, 1977.
Zhang, W. et al., “Synergistic Effects of Olanzapine and Other Antipsychotic Agents in Combination with Fluoxetine on Norepinephrine and Dopamine Release in Rat Prefrontal Cortex,”Neuropsychopharmacology, 2000, 23(3): 250-262.
Eliel, E.L.Stereochemistry of Carbon Compounds, McGraw-Hill, NY, 1962.
Remington's Pharmaceutical Sciences, 17th edition, ed. Alfonoso R. Gennaro, Mack Publishing Company, Easton, PA 1985.
Bundgaard, (ed.), Design of Prodrugs, Elsevier 1985.
Widder, et al. (ed.), Methods in Enzymology, vol. 4, Academic Press 1985.
Jacques, et al.,Enantiomers, Racemates and ResolutionsWiley Interscience, New York, 1981.
Higuchi and Stella (eds.)Prod
Deecher Darlene Coleman
Leventhal Liza
Merchenthaler Istvan Jozsef
O'Connor Lawrence Thomas
Sipe Kimberly Jean
Kim Jennifer
Wyeth
Zahner Joseph E.
LandOfFree
Use of norepinephrine reuptake modulators for preventing and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of norepinephrine reuptake modulators for preventing and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of norepinephrine reuptake modulators for preventing and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3941340